Catalyst Wire Dossier Catalyst Wire Dossier

TQB2450

Drug timelines are a Plus or Pro feature.

41 regulatory and trial events tracked for TQB2450, covering 2018-03-09 to 2026-04-07. Get the full timeline:

Most recent: Clinical Trial Update: A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression [Phase 2]

See pricing